Soy isoflavone phase II metabolism differs between rodents and humans: Implications for the effect on breast cancer risk

American Journal of Clinical Nutrition

Volumn 94, Issue 5, 2011, Pages 1284-1294

  Setchell, Kenneth D R ^a,b   Brown, Nadine M ^a   Zhao, Xueheng ^a   Lindley, Stephanie L ^a   Heubi, James E ^a,b   King, Eileen C ^a   Messina, Mark J ^c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Nutrition Matters Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENISTEIN; ISOFLAVONE; SOY ISOFLAVONE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; METABOLISM; NONHUMAN; NORMAL HUMAN; NUT; RAT; SOY NUT; SOYBEAN MILK;

ADULT; AGED; ANIMALS; BREAST; BREAST NEOPLASMS; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DISEASE MODELS, ANIMAL; FEMALE; GENISTEIN; HUMANS; INFANT; ISOFLAVONES; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; MIDDLE AGED; PREMENOPAUSE; RATS; RATS, SPRAGUE-DAWLEY; SOY FOODS; YOUNG ADULT;

ANIMALIA; MUS; RATTUS; RODENTIA;

EID: 80054953743     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.111.019638     Document Type: Article

References (70)

1. Cassidy A, Hooper L. Phytoestrogens and cardiovascular disease. J Br Menopause Soc 2006;12:49-56. (Pubitemid 43881063)
2. Li SH, Liu XX, Bai YY, Wang XJ, Sun K, Chen JZ, Hui RT. Effect of oral isoflavone supplementation on vascular endothelial function in postmenopausal women: a meta-analysis of randomized placebo-controlled trials. Am J Clin Nutr 2010;91:480-6.
3. Messina M, Lane B. Soy protein, soybean isoflavones, and coronary heart disease risk: where do we stand? Future Lipidol 2007;2:55-74. (Pubitemid 46812940)
4. Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer 2008;98:9-14.
5. Messina M, Wu AH. Perspectives on the soy-breast cancer relation. Am J Clin Nutr 2009;89:1673S-9S.
6. Yan L, Spitznagel EL. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr 2009;89:1155-63.
7. Bolaños R, Del Castillo A, Francia J. Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis. Menopause 2010;17:660-6.
8. Setchell KDR, Borriello SP, Kirk DN, Axelson M. Non-steroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutr 1984;40:569-78. (Pubitemid 14035518)
9. Coward L, Barnes NC, Setchell KDR, Barnes S. Genistein, daidzein, and their b-glycoside conjugates: antitumor isoflavones in soybean foods from American and Asian diets. J Agric Food Chem 1993;41:1961-7. (Pubitemid 2007019)
10. Franke AA, Custer LJ, Wang W, Shi CY. HPLC analysis of isoflavonoids and other phenolic agents from foods and from human fluids. Proc Soc Exp Biol Med 1998;217:263-73.
11. Brzezinski A, Debi A. Phytoestrogens: the "natural" selective estrogen receptor modulators? Eur J Obstet Gynecol Reprod Biol 1999;85:47-51. (Pubitemid 29248782)
12. Setchell KDR. Soy isoflavones-benefits and risks from nature's selective estrogen receptor modulators (SERMs). J Am Coll Nutr 2001;20:354S-62S; discussion 81S-83S.
13. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA° . Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139:4252-63. (Pubitemid 28513713)
14. Oseni T, Patel R, Pyle J, Jordan VC. Selective estrogen receptor modulators and phytoestrogens. Planta Med 2008;74:1656-65.
15. Murphy PA, Barua K, Hauck CC. Solvent extraction selection in the determination of isoflavones in soy foods. J Chromatogr B Analyt Technol Biomed Life Sci 2002;777:129-38. (Pubitemid 35257867)
16. Setchell KDR, Cole SJ. Variations in isoflavone levels in soy foods and soy protein isolates and issues related to isoflavone databases and food labeling. J Agric Food Chem 2003;51:4146-55.
17. Barnes S, Grubbs C, Setchell KDR, Carlson J. Soybeans inhibit mammary tumors in models of breast cancer. Prog Clin Biol Res 1990;347:239-53.
18. Helferich WG, Andrade JE, Hoagland MS. Phytoestrogens and breast cancer: a complex story. Inflammopharmacology 2008;16:219-26.
19. Hilakivi-Clarke L, Andrade JE, Helferich W. Is soy consumption good or bad for the breast? J Nutr 2010;140:2326S-34S.
20. Ju YH, Allred CD, Allred KF, Karko KL, Doerge DR, Helferich WG. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 2001;131:2957-62. (Pubitemid 33063130)
21. Ju YH, Fultz J, Allred KF, Doerge DR, Helferich WG. Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice. Carcinogenesis 2006;27:856-63.
22. Allred CD, Twaddle NC, Allred KF, Goeppinger TS, Churchwell MI, Ju YH, Helferich WG, Doerge DR. Soy processing affects metabolism and disposition of dietary isoflavones in ovariectomized BALB/c mice. J Agric Food Chem 2005;53:8542-50. (Pubitemid 41608911)
23. Allred CD, Allred KF, Ju YH, Goeppinger TS, Doerge DR, Helferich WG. Soy processing influences growth of estrogen-dependent breast cancer tumors. Carcinogenesis 2004;25:1649-57. (Pubitemid 39214307)
24. Doyle C, Kushi LH, Byers T, Courneya KS, Demark-Wahnefried W, Grant B, McTiernan A, Rock CL, Thompson C, Gansler T, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 2006;56:323-53. (Pubitemid 44903908)
25. Gu L, House SE, Prior RL, Fang N, Ronis MJ, Clarkson TB, Wilson ME. Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women. J Nutr 2006;136:1215-21.
26. Setchell KDR, Gosselin SJ, Welsh MB, Johnston JO, Balistreri WF, Kramer LW, Dresser BL, Tarr MJ. Dietary estrogens-a probable cause of infertility and liver disease in captive cheetahs. Gastroenterology 1987;93:225-33. (Pubitemid 17097584)
27. Doerge DR, Chang HC, Churchwell MI, Holder CL. Analysis of soy isoflavone conjugation in vitro and in human blood using liquid chromatography-mass spectrometry. Drug Metab Dispos 2000;28:298-307. (Pubitemid 30137054)
28. Dutton GJ. The influence of sex, species and strain on glucuronidation. CRC Press: Boca Raton, FL, 1980.
29. Setchell KDR, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, Cassidy A, Heubi JE. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001;131:1362S-75S. (Pubitemid 32268489)
30. Busby MG, Jeffcoat AR, Bloedon LT, Koch MA, Black T, Dix KJ, Heizer WD, Thomas BF, Hill JM, Crowell JA, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 2002;75:126-36. (Pubitemid 34013498)
31. Fischer L, Mahoney C, Jeffcoat AR, Koch MA, Thomas BE, Valentine JL, Stinchcomb T, Boan J, Crowell JA, Zeisel SH. Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer 2004;48:160-70. (Pubitemid 39045777)
32. Brown NM, Setchell KDR. Animal models impacted by phytoestrogens in commercial chow: implications for pathways influenced by hormones. Lab Invest 2001;81:735-47. (Pubitemid 32466536)
33. King RA, Bursill DB. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 1998;67:867-72. (Pubitemid 28196660)
34. Setchell KDR, Brown NM, Desai PB, Zimmer-Nechimias L, Wolfe B, Jakate AS, Creutzinger V, Heubi JE. Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J Nutr 2003;133:1027-35. (Pubitemid 36407120)
35. Setchell KDR, Cole SJ. Method of defining equol-producer status and its frequency among vegetarians. J Nutr 2006;136:2188-93. (Pubitemid 44156823)
36. Setchell KDR, Zhao X, Jha P, Heubi JE, Brown NM. The pharmacokinetic behavior of the soy isoflavone metabolite S-(-)equol and its diastereoisomer R-(+)equol in healthy adults determined by using stable-isotope-labeled tracers. Am J Clin Nutr 2009;90:1029-37.
37. Setchell KDR, Zimmer-Nechemias L, Cai J, Heubi JE. Exposure of infants to phyto-oestrogens from soy-based infant formula. Lancet 1997;350:23-7.
38. Setchell KDR, Zimmer-Nechemias L, Cai J, Heubi JE. Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Am J Clin Nutr 1998;68(Suppl):1453S-61S. (Pubitemid 28550929)
39. Setchell KDR, Zhao X, Shoaf SE, Ragland K. The pharmacokinetics of S-(-)equol administered as SE5-OH tablets to healthy postmenopausal women. J Nutr 2009;139:2037-43.
40. Setchell KDR, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, Wolfe B, Zimmer-Nechemias L, Brown NM, Lund TD, et al. S-equol, a potent ligand for estrogen receptor b, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 2005;81:1072-9. (Pubitemid 41724948)
41. Setchell KDR, Clerici C. Equol: pharmacokinetics and biological actions. J Nutr 2010;140:1363S-8S.
42. Murphy P, Tongtong S, Buseman G, Barua K. Isoflavones in soy-based infant formulas. J Agric Food Chem 1997;45:4635-8. (Pubitemid 127485817)
43. Clerici C, Setchell KDR, Battezzati PM, Pirro M, Giuliano V, Asciutti S, Castellani D, Nardi E, Sabatino G, Orlandi S, et al. Pasta naturally enriched with isoflavone aglycons from soy germ reduces serum lipids and improves markers of cardiovascular risk. J Nutr 2007;137:2270-8. (Pubitemid 47529589)
44. Shelnutt SR, Cimino CO, Wiggins PA, Badger TM. Urinary pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein. Cancer Epidemiol Biomarkers Prev 2000;9:413-9. (Pubitemid 30265785)
45. Pritchett LE, Atherton KM, Mutch E, Ford D. Glucuronidation of the soyabean isoflavones genistein and daidzein by human liver is related to levels of UGT1A1 and UGT1A9 activity and alters isoflavone response in the MCF-7 human breast cancer cell line. J Nutr Biochem 2008;19:739-45.
46. Zhang Y, Song TT, Cunnick JE, Murphy PA, Hendrich S. Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations. J Nutr 1999;129:399-405. (Pubitemid 29072127)
47. Setchell KDR, Brown NM, Zimmer-Nechemias L, Brashear WT, Wolfe BE, Kirschner AS, Heubi JE. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr 2002;76:447-53. (Pubitemid 34804071)
48. Santell RC, Chang YC, Nair MG, Helferich WG. Dietary genistein exerts estrogenic effects upon the uterus, mammary gland and the hypothalamic/pituitary axis in rats. J Nutr 1997;127:263-9. (Pubitemid 27079955)
49. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. (Published erratum appears in Cancer Res 1999;59:1388.) Cancer Res 1998;58:3833-8. (Pubitemid 28405638)
50. Santell RC, Kieu N, Helferich WG. Genistein inhibits growth of estrogen-independent human breast cancer cells in culture but not in athymic mice. J Nutr 2000;130:1665-9. (Pubitemid 30451050)
51. Huggett AC, Pridmore S, Malnoe A, Haschke F, Offord EA. Phyto-oestrogens in soy-based infant formula. [letter; comment] Lancet 1997;350:815-6.
52. Badger TM, Ronis MJ, Hakkak R, Rowlands JC, Korourian S. The health consequences of early soy consumption. J Nutr 2002;132:559S-65S. (Pubitemid 34208770)
53. Badger TM, Gilchrist JM, Pivik RT, Andres A, Shankar K, Chen JR, Ronis MJ. The health implications of soy infant formula. Am J Clin Nutr 2009;89:1668S-72S.
54. Franke AA, Custer LJ, Tanaka Y. Isoflavones in human breast milk and other biological fluids. Am J Clin Nutr 1998;68(Suppl):1466S-73S. (Pubitemid 28550931)
55. Tousen Y, Ezaki J, Fujii Y, Ueno T, Nishimuta M, Ishimi Y. Natural S-equol decreases bone resorption in postmenopausal, non-equol-producing Japanese women: a pilot randomized, placebo-controlled trial. Menopause 2011;18(5):563-74.
56. Aso T. Equol improves menopausal symptoms in Japanese women. J Nutr 2010;140:1386S-9S.
57. Schwen R, Jackson R, Proudlock R. Genotoxicity assessment of S-equol in bacterial mutation, chromosomal aberration, and rodent bone marrow micronucleus tests. Food Chem Toxicol 2010;48:3481-5.
58. Jackson RL, Greiwe JS, Desai PB, Schwen RJ. Single-dose and steady-state pharmacokinetic studies of S-equol, a potent nonhormonal, estrogen receptor beta-agonist being developed for the treatment of menopausal symptoms. Menopause 2011;18:185-93.
59. Messina MJ, Wood CE. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J 2008;7:17.
60. Hooper L, Madhavan G, Tice JA, Leinster SJ, Cassidy A. Effects of isoflavones on breast density in pre- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. Hum Reprod Update 2010;16:745-60.
61. Lundström E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric 2001;4:42-8. (Pubitemid 32448486)
62. Conner P, Soderqvist G, Skoog L, Graser T, Walter F, Tani E, Carlstrom K, von Schoultz B. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat 2003;78:159-65.
63. Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 2005;11:545-60. (Pubitemid 41631306)
64. Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, Lu W. Soy food intake and breast cancer survival. JAMA 2009;302:2437-43.
65. Kang X, Zhang Q, Wang S, Huang X, Jin S. Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. CMAJ 2010;182:1857-62.
66. Guha N, Kwan ML, Quesenberry CP Jr, Weltzien EK, Castillo AL, Caan BJ. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat 2009;118:395-405.
67. Caan BJ, Natarajan L, Parker BA, Gold EB, Thomson CA, Newman VA, Rock CL, Pu M, Al Delaimy WK, Pierce JP. Soy food consumption and breast cancer prognosis. Cancer Epidemiol Biomarkers Prev 2011;20:854-8.
68. Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002;62:2474-7. (Pubitemid 34462720)
69. Ju YH, Doerge DR, Woodling KA, Hartman JA, Kwak J, Helferich WG. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 2008;29:2162-8.
70. Ju YH, Allred KF, Allred CD, Helferich WG. Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis 2006;27:1292-9. (Pubitemid 43994865)